Proffered Presentations Archive

UK & Ireland Prostate Brachytherapy Conference 2024

Abstract number 16 

QOL outcomes in patients receiving Low dose rate brachytherapy boost with EBRT for unfavorable intermediate and high risk prostate cancer: A single institution experience

Dr Mansoor Qayoumi, Dr Muhammad Faisal Jamaluddin, Fiona Keating, Admire Dzingwa
Cork University Hospital 

Purpose: This retrospective study aims to evaluate the genitourinary (GU), gastrointestinal (GI) morbidity and sexual dysfunction for men diagnosed with unfavorable intermediate and high risk prostate patients who received combination EBRT and Brachytherapy Boost at our institution in the past 10 years. 

Methods: We performed chart review on all patients treated with EBRT and BT combined treatment between 2013 and 2023. Patients with unfavorable intermediate and high risk prostate cancer were offered BT boost with or without Androgen Deprivation Therapy. EBRT was prescribed to 46 Gy and BT boost using I125 were prescribed to 110Gy, 1 to 4 weeks after EBRT. The technique for EBRT were 3D Conformal and at a later stage VMAT. Prior to the initiation of the treatment, patients underwent pre-treatment assessments, during which baseline data on quality of life symptoms were recorded. Clinical follow-ups were conducted at weekly intervals during the EBRT sessions, and additional assessments were performed 1 month, 6 months, and then annually after the brachytherapy boost. Modified LENT-SOMA scale was used as criteria for G3 genitourinary (GU) and gastrointestinal (GI) morbidity, along with specific information on urinary incontinence, catheter use, and erectile function that were identified. 

Results: 57 male participants with a median age of 66 were treated with BT Boost of which 50 received ADT for at least 1 year duration. The median follow-up duration was 2 years (ranging from 6 months to 5 years). The overall incidence of grade 3 and above urinary tract and gastrointestinal symptoms during any point in the follow-ups were 1.7% and 1.7% respectively. Concerning sexual function, a substantial decline compared to baseline occurred in 12 patients, representing 21% of the study cohort. 

Conclusion: Our study demonstrated lower occurrences of grade 3 genitourinary (GU), gastrointestinal (GI), and sexual toxicities in comparison to randomized international trials. 

References: 

1. Sree Rodda et al., ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics 98, no. 2 (2017): 295 
2. Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:275-285. 
3. Morton GC, Hoskins PJ. Brachytherapy: Current status and future strategies can high dose rate replace low dose rate and external beam radiotherapy? Clin Oncol (R Coll Radiol) 2013;25:474-482.
4. Keyes M, Miller S, Pickles T, et al. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: Population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals. Int J Radiat Oncol Biol Phys 2014;90: 570-578.
5. Tward JD, Jarosek RN, Chu H, et al. Time course and accumulated risk of severe urinary adverse events after high- versus low-dose-rate prostate brachytherapy with and without external beam radiation therapy. Int J Radiat Oncol Biol Phys 2016;95:1443-1453.